ACAD Acadia Pharmaceuticals Inc

Price (delayed)

$21.46

Market cap

$3.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.65

Enterprise value

$3.19B

Highlights
ACAD's gross profit is up by 26% year-on-year and by 4% since the previous quarter
ACAD's revenue is up by 25% YoY and by 3.7% QoQ
The net income has declined by 9% year-on-year but it is up by 8% since the previous quarter
The EPS has increased by 8% QoQ but it has decreased by 4.4% YoY
The debt has increased by 36% QoQ
The quick ratio has declined by 17% year-on-year and by 10% since the previous quarter

Key stats

What are the main financial stats of ACAD
Market
Shares outstanding
160.18M
Market cap
$3.44B
Enterprise value
$3.19B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.91
Price to sales (P/S)
7.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.96
Earnings
Revenue
$458.24M
EBIT
-$259.38M
EBITDA
-$256.21M
Free cash flow
-$155.04M
Per share
EPS
-$1.65
Free cash flow per share
-$0.97
Book value per share
$3.63
Revenue per share
$2.86
TBVPS
$4.71
Balance sheet
Total assets
$755.17M
Total liabilities
$173.57M
Debt
$60.58M
Equity
$581.61M
Working capital
$564.61M
Liquidity
Debt to equity
0.1
Current ratio
6.16
Quick ratio
5.86
Net debt/EBITDA
0.97
Margins
EBITDA margin
-55.9%
Gross margin
97.9%
Net margin
-56.7%
Operating margin
-57.6%
Efficiency
Return on assets
-33.6%
Return on equity
-41.2%
Return on invested capital
-72.4%
Return on capital employed
-40.2%
Return on sales
-56.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACAD stock price

How has the Acadia Pharmaceuticals stock price performed over time
Intraday
-3.46%
1 week
-8.68%
1 month
-12.48%
1 year
-50.95%
YTD
-59.86%
QTD
-12.01%

Financial performance

How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$458.24M
Gross profit
$448.64M
Operating income
-$263.84M
Net income
-$260.01M
Gross margin
97.9%
Net margin
-56.7%
ACAD's gross profit is up by 26% year-on-year and by 4% since the previous quarter
ACAD's revenue is up by 25% YoY and by 3.7% QoQ
The operating margin has increased by 15% YoY and by 11% QoQ
The net margin has increased by 13% YoY and by 11% QoQ

Growth

What is Acadia Pharmaceuticals's growth rate over time

Valuation

What is Acadia Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.91
P/S
7.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.96
The EPS has increased by 8% QoQ but it has decreased by 4.4% YoY
ACAD's price to book (P/B) is 44% lower than its last 4 quarters average of 10.5 and 36% lower than its 5-year quarterly average of 9.2
The company's equity fell by 9% YoY and by 7% QoQ
ACAD's P/S is 89% below its 5-year quarterly average of 70.8 and 52% below its last 4 quarters average of 15.7
ACAD's revenue is up by 25% YoY and by 3.7% QoQ

Efficiency

How efficient is Acadia Pharmaceuticals business performance
ACAD's return on invested capital is down by 24% year-on-year but it is up by 2.7% since the previous quarter
The ROS has increased by 13% YoY and by 11% QoQ
Acadia Pharmaceuticals's return on assets has increased by 8% QoQ and by 2.6% YoY
The ROE has grown by 6% from the previous quarter but it has contracted by 4.6% YoY

Dividends

What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACAD.

Financial health

How did Acadia Pharmaceuticals financials performed over time
The total liabilities has soared by 59% YoY and by 12% QoQ
The quick ratio has declined by 17% year-on-year and by 10% since the previous quarter
The debt is 90% lower than the equity
The debt to equity has grown by 43% since the previous quarter
The debt has increased by 36% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.